What we do Bharat Parenterals Ltd manufactures pharmaceutical formulations, life-saving drugs, parenterals, and ayurvedic products, operating a modern WHO-standard plant in Baroda, India. |
Founded in 1,992 |
Market share Leading pharma manufacturer with expanding presence in India, emerging markets, and regulated markets like US and EU. |
Problem solved Provides quality drugs addressing critical care, anesthesia, pain management, and life-saving treatments for institutional and global markets. |
Top clients or who we serve Serves hospitals, healthcare institutions, and global pharmaceutical partners; operates in B2B and B2C segments. |
Key management - |
Our journey and innovations Founded in 1992; expanded through setting up subsidiaries and obtaining USFDA, EU GMP approvals, pioneering specialty injectables and complex generics. |
Where we operate India, Africa, Latin America, Southeast Asia, Middle East, US, and Europe. |
Top products or what we offer Finished dosage forms in injectables, tablets, capsules; specialty therapeutics including oncology, CNS, and anti-infectives. |
Top brands Key brands include institutional anesthesia and critical care injectables with growing specialty portfolios. |
Raw materials needed Active pharmaceutical ingredients, excipients for formulation and packaging materials. |
Raw materials supplier Various regulated suppliers; specific names undisclosed. |
Recurring vs cyclical contribution Revenue mix includes recurring sales to institutional clients and cyclical product launches. |
Our industry position Strong position in Indian pharma and emerging markets; growing regulated market footprint via subsidiaries. |
Financial highlights FY25 standalone revenue Rs. 318.7 crore, PAT Rs. 26.4 crore; consolidated revenue Rs. 340.4 crore with ongoing investments. |
Geographical revenue split Revenue split: ~33% India, ~67% international markets including US, Europe, Africa, LATAM. |
Order book Robust order book of Rs. 303 crore providing revenue visibility for FY27 growth. |
Whats driving growth Growth driven by geographic expansion, specialty product launches, regulatory approvals, and strategic partnerships. |
Our future plans Focus on scaling regulated market CDMO, expanding subsidiaries, and entering new emerging markets by FY27. |
Our green promise Awarded Green Gujarat Award; continuous energy conservation and environmental compliance initiatives. |
Our people and values Diverse workforce with strong ethics, Code of Conduct adherence, and zero tolerance for workplace harassment. |
Key challenges ahead Navigating regulatory complexities, competition, and managing costs during scale-up phases. |
Interesting facts India's only USFDA-approved oncology oral liquid manufacturer; awarded Manufacturing SME of the Year in Health & Pharma 2025. |
Risks and strategy Mitigates development, regulatory, and commercial risks with experienced leadership, state-of-the-art facilities, and strategic partnerships. |
